6 citations
,
April 2022 in “The Breast” This study found that scalp cooling significantly reduced chemotherapy-induced hair loss in breast cancer patients, especially those receiving taxane monotherapy, but did not significantly affect hair regrowth after chemotherapy.
November 2025 in “npj Breast Cancer” In this study of women with breast cancer undergoing chemotherapy and scalp cooling, 12% experienced incomplete hair regrowth at 6 months, with tamoxifen therapy identified as a significant risk factor for persistent chemotherapy-induced alopecia.
April 2026 in “Actas Dermo-Sifiliográficas” This study reports that scalp cooling therapies and minoxidil may promote hair regrowth in patients experiencing persistent chemotherapy-induced alopecia, with trichoscopy aiding in treatment assessment.
141 citations
,
September 2016 in “European Journal of Dermatology” This review examines dermatological side effects of taxane chemotherapy reported in past studies and highlights the necessity for identifying and managing these conditions to maintain cancer patients' quality of life; it presents no new clinical results.
9 citations
,
February 2012 in “Cancer Chemotherapy and Pharmacology” The combination of gemcitabine and vinorelbine is effective and safe for treating elderly patients with advanced breast cancer previously treated with anthracyclines and taxanes.